4.3 Article

Lenvatinib-related renal microangiopathy: a case series

期刊

VIRCHOWS ARCHIV
卷 480, 期 2, 页码 467-473

出版社

SPRINGER
DOI: 10.1007/s00428-021-03114-5

关键词

Lenvatinib; Thrombotic microangiopathy; Kidney biopsy; Proteinuria; Onco-nephrology

向作者/读者索取更多资源

Tyrosine kinase inhibitors, such as lenvatinib, are commonly used in cancer treatment but can lead to renal thrombotic microangiopathy (TMA). Managing lenvatinib-induced renal TMA remains challenging, with uncertainty about the best therapy. Early adjustment of drug dosages may help prevent further damage and treatment discontinuation.
Tyrosine kinase inhibitors play an important role in the armamentarium against cancer. Lenvatinib is a multiple kinase inhibitor approved by the Food and Drugs Administration (FDA) for the treatment of advanced and radioresistant thyroid carcinomas and, in combination with everolimus, for renal cell carcinoma and unresectable hepatocellular carcinoma. The anti-tumoral activity is largely dependent on inhibition of neo-angiogenesis, and established side effects of anti-angiogenetic therapeutics include renal thrombotic microangiopathy (TMA). Here, we describe three cases of biopsy-proven renal TMA clinically presenting with proteinuria and stable serum creatinine in patients receiving lenvatinib for thyroid cancer. Microangiopathic lesions included glomerular basement membrane reduplication with segmental cellular interposition, mesangiolysis, and focal intracapillary and arteriolar thrombi. Drug-dose reduction or withdrawal was effective in renal function preservation, but cancer progressed in all patients. The management of lenvatinib-induced renal TMA remains a challenge. The best therapy in these patients is still uncertain. Earlier and more precise measurement of urine protein levels, allowing for early dose adjustment, could be effective in preventing further damage and drug discontinuation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据